Cargando…

Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay

The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There have been man...

Descripción completa

Detalles Bibliográficos
Autores principales: Holzer, Max, Schade, Nico, Opitz, Ansgar, Hilbrich, Isabel, Stieler, Jens, Vogel, Tim, Neukel, Valentina, Oberstadt, Moritz, Totzke, Frank, Schächtele, Christoph, Sippl, Wolfgang, Hilgeroth, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225193/
https://www.ncbi.nlm.nih.gov/pubmed/30213139
http://dx.doi.org/10.3390/molecules23092335
_version_ 1783369719361830912
author Holzer, Max
Schade, Nico
Opitz, Ansgar
Hilbrich, Isabel
Stieler, Jens
Vogel, Tim
Neukel, Valentina
Oberstadt, Moritz
Totzke, Frank
Schächtele, Christoph
Sippl, Wolfgang
Hilgeroth, Andreas
author_facet Holzer, Max
Schade, Nico
Opitz, Ansgar
Hilbrich, Isabel
Stieler, Jens
Vogel, Tim
Neukel, Valentina
Oberstadt, Moritz
Totzke, Frank
Schächtele, Christoph
Sippl, Wolfgang
Hilgeroth, Andreas
author_sort Holzer, Max
collection PubMed
description The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There have been many approaches for a reduction of toxic Aβ peptides which mostly failed to halt cognitive deterioration in patients. The formation of neurofibrillary tangles (NFT) and its precursor tau oligomers have been suggested as main cause of neuronal degeneration because of a direct correlation of their density to the degree of dementia. Reducing of tau aggregation may be a viable approach for the treatment of AD. NFT consist of hyperphosphorylated tau protein and tau hyperphosphorylation reduces microtubule binding. Several protein kinases are discussed to be involved in tau hyperphosphorylation. We developed novel inhibitors of three protein kinases (gsk-3β, cdk5, and cdk1) and discussed their activity in relation to tau phosphorylation and on tau–tau interaction as a nucleation stage of a tau aggregation in cells. Strongest effects were observed for those inhibitors with effects on all the three kinases with emphasis on gsk-3β in nanomolar ranges.
format Online
Article
Text
id pubmed-6225193
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62251932018-11-13 Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay Holzer, Max Schade, Nico Opitz, Ansgar Hilbrich, Isabel Stieler, Jens Vogel, Tim Neukel, Valentina Oberstadt, Moritz Totzke, Frank Schächtele, Christoph Sippl, Wolfgang Hilgeroth, Andreas Molecules Communication The current number of drugs available for the treatment of Alzheimer’s disease (AD) is strongly limited and their benefit for therapy is given only in the early state of the disease. An effective therapy should affect those processes which mainly contribute to the neuronal decay. There have been many approaches for a reduction of toxic Aβ peptides which mostly failed to halt cognitive deterioration in patients. The formation of neurofibrillary tangles (NFT) and its precursor tau oligomers have been suggested as main cause of neuronal degeneration because of a direct correlation of their density to the degree of dementia. Reducing of tau aggregation may be a viable approach for the treatment of AD. NFT consist of hyperphosphorylated tau protein and tau hyperphosphorylation reduces microtubule binding. Several protein kinases are discussed to be involved in tau hyperphosphorylation. We developed novel inhibitors of three protein kinases (gsk-3β, cdk5, and cdk1) and discussed their activity in relation to tau phosphorylation and on tau–tau interaction as a nucleation stage of a tau aggregation in cells. Strongest effects were observed for those inhibitors with effects on all the three kinases with emphasis on gsk-3β in nanomolar ranges. MDPI 2018-09-12 /pmc/articles/PMC6225193/ /pubmed/30213139 http://dx.doi.org/10.3390/molecules23092335 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Holzer, Max
Schade, Nico
Opitz, Ansgar
Hilbrich, Isabel
Stieler, Jens
Vogel, Tim
Neukel, Valentina
Oberstadt, Moritz
Totzke, Frank
Schächtele, Christoph
Sippl, Wolfgang
Hilgeroth, Andreas
Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
title Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
title_full Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
title_fullStr Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
title_full_unstemmed Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
title_short Novel Protein Kinase Inhibitors Related to Tau Pathology Modulate Tau Protein-Self Interaction Using a Luciferase Complementation Assay
title_sort novel protein kinase inhibitors related to tau pathology modulate tau protein-self interaction using a luciferase complementation assay
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225193/
https://www.ncbi.nlm.nih.gov/pubmed/30213139
http://dx.doi.org/10.3390/molecules23092335
work_keys_str_mv AT holzermax novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT schadenico novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT opitzansgar novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT hilbrichisabel novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT stielerjens novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT vogeltim novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT neukelvalentina novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT oberstadtmoritz novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT totzkefrank novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT schachtelechristoph novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT sipplwolfgang novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay
AT hilgerothandreas novelproteinkinaseinhibitorsrelatedtotaupathologymodulatetauproteinselfinteractionusingaluciferasecomplementationassay